Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses

MLA

van Eck van der Sluijs, Jesper, et al. “Clinically Applicable CD34+-Derived Blood Dendritic Cell Subsets Exhibit Key Subset-Specific Features and Potently Boost Anti-Tumor T and NK Cell Responses.” Cancer Immunology, Immunotherapy, vol. 70, Apr. 2021, pp. 3167–81. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....40bb21c842e1ed76bcbe581dc3ed9e03&authtype=sso&custid=ns315887.

APA

van Eck van der Sluijs, J., van Ens, D., Thordardottir, S., Vodegel, D., Hermens, I., van der Waart, A. B., Falkenburg, J. H. F., Kester, M. G. D., de Rink, I., Heemskerk, M. H. M., Borst, J., Schaap, N. P. M., Jansen, J. H., Xiao, Y., Dolstra, H., & Hobo, W. (2021). Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses. Cancer Immunology, Immunotherapy, 70, 3167–3181.

Chicago

van Eck van der Sluijs, Jesper, Diede van Ens, Soley Thordardottir, Denise Vodegel, Inge Hermens, Anniek B. van der Waart, J. H. Frederik Falkenburg, et al. 2021. “Clinically Applicable CD34+-Derived Blood Dendritic Cell Subsets Exhibit Key Subset-Specific Features and Potently Boost Anti-Tumor T and NK Cell Responses.” Cancer Immunology, Immunotherapy 70 (April): 3167–81. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....40bb21c842e1ed76bcbe581dc3ed9e03&authtype=sso&custid=ns315887.